**Figure S1.** Performance of 106-CDS panel with the other cut-points for predicting the efficacy of immunotherapy.

Fig S1

**Figure S1.** Performance of 106-CDS panel with the other cut-points for predicting the efficacy of immunotherapy. a Kaplan–Meier curves of progression-free survival (PFS) for 59 advanced lung adenocarcinoma (LUAD) patients in the Matthew dataset, using the 106-CDS panel with the cut-point of the upper quartiles. b Kaplan–Meier curves of progression-free survival (PFS) for 59 advanced lung adenocarcinoma (LUAD) patients in the Matthew dataset, using the 106-CDS panel with the cut-point of the upper tertiles. c Kaplan–Meier curves of progression-free survival (PFS) for 29 advanced lung adenocarcinoma (LUAD) patients in the Rizvi dataset, using the 106-CDS panel with the cut-point of the upper quartiles. d Kaplan–Meier curves of progression-free survival (PFS) for 29 advanced lung adenocarcinoma (LUAD) patients in the Rizvi dataset, using the 106-CDS panel with the cut-point of the upper tertiles. The hazard ratio (HR) and 95% confidence interval (CI) were determined using univariate Cox regression models